Home >> Research Area >>GPCR/G protein>>Cannabinoid Receptor>> Palmitoylisopropylamide

Palmitoylisopropylamide

Inhibitor of FAAH CAS# 189939-61-5

Palmitoylisopropylamide

Catalog No. BCC7187----Order now to get a substantial discount!

Product Name & Size Price Stock
Palmitoylisopropylamide: 5mg $58 In Stock
Palmitoylisopropylamide: 10mg Please Inquire In Stock
Palmitoylisopropylamide: 20mg Please Inquire Please Inquire
Palmitoylisopropylamide: 50mg Please Inquire Please Inquire
Palmitoylisopropylamide: 100mg Please Inquire Please Inquire
Palmitoylisopropylamide: 200mg Please Inquire Please Inquire
Palmitoylisopropylamide: 500mg Please Inquire Please Inquire
Palmitoylisopropylamide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Palmitoylisopropylamide

Number of papers citing our products

Chemical structure

Palmitoylisopropylamide

3D structure

Chemical Properties of Palmitoylisopropylamide

Cas No. 189939-61-5 SDF Download SDF
PubChem ID 5063962 Appearance Powder
Formula C19H39NO M.Wt 297.52
Type of Compound N/A Storage Desiccate at -20°C
Synonyms PIA
Solubility Soluble to 100 mM in ethanol and to 10 mM in DMSO
Chemical Name N-propan-2-ylhexadecanamide
SMILES CCCCCCCCCCCCCCCC(=O)NC(C)C
Standard InChIKey TZYVUGCYYQOTQR-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H39NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(21)20-18(2)3/h18H,4-17H2,1-3H3,(H,20,21)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Palmitoylisopropylamide

DescriptionInhibitor of fatty acid amide hydrolase (FAAH); pIC50 = 4.89 for inhibition of [3H]-anandamide metabolism. Displays little binding to CB1 and CB2 receptors (IC50 > 100 μM) and very weakly blocks anandamide uptake (IC50 ~ 100 μM). Inhibits proliferation of C6 glioma cells.

Palmitoylisopropylamide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Palmitoylisopropylamide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Palmitoylisopropylamide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3611 mL 16.8056 mL 33.6112 mL 67.2224 mL 84.028 mL
5 mM 0.6722 mL 3.3611 mL 6.7222 mL 13.4445 mL 16.8056 mL
10 mM 0.3361 mL 1.6806 mL 3.3611 mL 6.7222 mL 8.4028 mL
50 mM 0.0672 mL 0.3361 mL 0.6722 mL 1.3444 mL 1.6806 mL
100 mM 0.0336 mL 0.1681 mL 0.3361 mL 0.6722 mL 0.8403 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Palmitoylisopropylamide

Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.[Pubmed:11498512]

Br J Pharmacol. 2001 Aug;133(8):1263-75.

1. The ability of a series of homologues and analogues of palmitoylethanolamide to inhibit the uptake and fatty acid amidohydrolase (FAAH)-catalysed hydrolysis of [(3)H]-anandamide ([(3)H]-AEA) has been investigated. 2. Palmitoylethanolamide and homologues with chain lengths from 12 - 18 carbon atoms inhibited rat brain [(3)H]-AEA metabolism with pI(50) values of approximately 5. Homologues with chain lengths < or = eight carbon atoms gave < 20% inhibition at 100 microM. 3. R-palmitoyl-(2-methyl)ethanolamide, Palmitoylisopropylamide and oleoylethanolamide inhibited [(3)H]-AEA metabolism with pI(50) values of 5.39 (competitive inhibition), 4.89 (mixed type inhibition) and 5.33 (mixed type inhibition), respectively. 4. With the exception of oleoylethanolamide, the compounds did not produce dramatic inhibition of [(3)H]-WIN 55,212-2 binding to human CB(2) receptors expressed on CHO cells. Palmitoylethanolamide, Palmitoylisopropylamide and R-palmitoyl-(2-methyl)ethanolamide had modest effects upon [(3)H]-CP 55,940 binding to human CB(1) receptors expressed on CHO cells. 5. Most of the compounds had little effect upon the uptake of [(3)H]-AEA into C6 and/or RBL-2H3 cells. However, palmitoylcyclohexamide (100 microM) and Palmitoylisopropylamide (30 and 100 microM) produced more inhibition of [(3)H]-AEA uptake than expected to result from inhibition of [(3)H]-AEA metabolism alone. 6. In intact C6 cells, Palmitoylisopropylamide and oleoylethanolamide inhibited formation of [(3)H]-ethanolamine from [(3)H]-AEA to a similar extent as AM404, whereas palmitoylethanolamide, palmitoylcyclohexamide and R-palmitoyl-(2-methyl)ethanolamide were less effective. 7. These data provide useful information upon the ability of palmitoylethanolamide analogues to act as 'entourage' compounds. Palmitoylisopropylamide may prove useful as a template for design of compounds that reduce the cellular accumulation and metabolism of AEA without affecting either CB(1) or CB(2) receptors.

AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide.[Pubmed:12698235]

Arch Toxicol. 2003 Apr;77(4):201-7.

AM404 [ N-(4-hydroxyphenyl)arachidonylamide] and VDM 11 [(5 Z,8 Z,11 Z,14 Z)- N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide] are commonly used to prevent the cellular accumulation of the endocannabinoid anandamide, and thereby to potentiate its actions. However, it has been reported that AM404 can produce an influx of calcium into cells, which might be expected to have deleterious effects on cell proliferation. In the present study, AM404 and VDM 11 were found to reduce C6 glioma cell proliferation with IC(50) values of 4.9 and 2.7 microM, respectively. The inhibition of cell proliferation following a 96-h exposure was not accompanied by dramatic caspase activation, and was not prevented by either a combination of cannabinoid and vanilloid receptor antagonists, or by the antioxidant alpha-tocopherol, suggestive of a non-specific mode of action. Similar results were seen with Palmitoylisopropylamide, although this compound only produced significant inhibition of cell proliferation at 30 microM concentrations. AM404 (1 microM), VDM 11 (1 microM) and Palmitoylisopropylamide (3-30 microM), i.e. concentrations producing relatively modest effects on cell proliferation per se, reduced the vanilloid receptor-mediated antiproliferative effects of anandamide, as would be expected for compounds preventing the cellular accumulation of anandamide (and thereby access to its binding site on the vanilloid receptor). It is concluded that concentrations of AM404 and VDM 11 that are generally used to reduce the cellular accumulation of anandamide have deleterious effects upon cell proliferation, and that lower concentrations of these compounds may be more appropriate to use in vitro.

Keywords:

Palmitoylisopropylamide,189939-61-5,PIA,Natural Products,Cannabinoid Receptor, buy Palmitoylisopropylamide , Palmitoylisopropylamide supplier , purchase Palmitoylisopropylamide , Palmitoylisopropylamide cost , Palmitoylisopropylamide manufacturer , order Palmitoylisopropylamide , high purity Palmitoylisopropylamide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: